Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

Cell reports - 11 Sept 2014

Lamba Simona, Russo Mariangela, Sun Chong, Lazzari Luca, Cancelliere Carlotta, Grernrum Wipawadee, Lieftink Cor, Bernards Rene, Di Nicolantonio Federica, Bardelli Alberto

Abstract excerpt

KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available to treat KRAS mutant cancers. We used two independent reverse genetic approaches to identify components of the RAS-signaling pathways required for growth of KRAS mutant tumors. Small interfering RNA (siRNA) screening of 37 KRAS mutant colorectal cancer cell lines showed that RAF1 suppression was synthetic lethal with MEK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to BRAF gene

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 25199829
DOI: 10.1016/j.celrep.2014.07.033

Genes

KRAS
RAF1
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.PMID 25199829Read ↗

A combinatorial strategy for treating KRAS-mutant lung cancer.Semantic proximity Read ↗

Targeting the MAPK Pathway in KRAS-Driven Tumors.Semantic proximity Read ↗

EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.Semantic proximity Read ↗

MEK and RAF inhibitors for BRAF-mutated cancersSemantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

KRAS and BRAF: drug targets and predictive biomarkers.Semantic proximity Read ↗

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survivalSemantic proximity Read ↗

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.Semantic proximity Read ↗

Targeting the MAPK Pathway in RAS Mutant Cancers.Semantic proximity Read ↗

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Semantic proximity Read ↗

Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Semantic proximity Read ↗

Combinatorial strategies to target RAS-driven cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.